Worcester, MA DPS Group and Hodess Cleanroom Construction have completed a proprietary cell therapy manufacturing facility for Mustang Bio, Inc., a clinical-stage biopharmaceutical company. Mustang Bio engaged Hodess as prime consultant on the design/build project, and Hodess selected DPS Group for its depth of experience designing current cGMP manufacturing facilities. DPS Group’s Boston office provided architectural and engineering services for the new facility.
Located within UMass Medicine Science Park, the 27,000 s/f facility will support the clinical development and commercialization of Mustang’s CAR T and gene therapy product candidates and enable proprietary cell therapy research. The project focused on upgrading existing office and laboratory space, and converting existing labs into three cGMP ISO7 clinical production areas. The flexible design met Mustang’s current workplace and manufacturing needs in 12,000 s/f of the facility, providing space for future expansion. Other facility improvements included HVAC, mechanical, and fire protection system upgrades and the installation of a new air handling unit customized for increased air flow to the cGMP spaces. Energy efficient lighting and lighting controls were also added.
“The opening of our cell therapy manufacturing facility is a significant milestone for Mustang Bio because it will enable us to process personalized cell therapies for the treatment of aggressive forms of cancer and continue to advance the research in support of our gene therapy for X-linked severe combined immunodeficiency (X-SCID),” said Manuel Litchman, M.D., president and CEO of Mustang Bio. “DPS Group and Hodess Construction brought a seamless design/build approach and expertise in cleanroom design and construction that helped successfully complete the project. We look forward to growing our clinical and chemistry, manufacturing and controls teams in this specialized facility.”